Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
Orencia’s late-stage failure in Sjögren’s has dashed hopes of a therapy soon, but the mid-stage pipeline is crowded, with Novartis, Glaxosmithkline and Galapagos all…
With the company’s Molgradex failing to beat standard of care in a rare lung disorder, the premise behind this project looks questionable.
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
After last year’s flop of Prothena’s NEOD001, Takeda’s Ninlaro fails to treat the underlying cause of the non-genetic form of this disease.
In the wake of two phase III glioblastoma failures this month, from Abbvie and Bristol-Myers Squibb, hopes dim for another big readout from Tocagen.
A flop in a small depression trial hits Vistagen Therapeutics, but the group insists that all is well ahead of its main event.
Genkyotex has dredged the data to find a glimmer of hope with GKT831 in primary biliary cholangitis, but cash is running short.
Presentations from Assembly Biosciences and Spring Bank Pharmaceuticals could disappoint those hoping to see more definitive steps towards a functional cure for hepatitis…